Active Pharmaceutical Ingredients/API Market by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormone) Drug (OTC, Rx), Therapy (Diabetes, Oncology, CNS, CVD) - Global Forecast to 2021

Date: January 10, 2017
Pages: 315
Price:
US$ 5,650.00
License [?]:
Publisher: MarketsandMarkets
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: GFEBC7D7223EN
Leaflet:

Download PDF Leaflet

Active Pharmaceutical Ingredients/API Market by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormone) Drug (OTC, Rx), Therapy (Diabetes, Oncology, CNS, CVD) - Global Forecast to 2021
The active pharmaceutical ingredients market in terms of value is expected to reach USD 213.97 billion by 2021 from USD 157.95 billion in 2016, growing at a CAGR of 6.3% from 2016 to 2021. This market is categorized on the basis of type, type of manufacturer, type of synthesis, type of drug, therapeutic application, and region.

Major factors contributing to the growth of the active pharmaceutical ingredients market include increasing incidence of chronic diseases, rising prevalence of cancer, technological advancements in API manufacturing, growing importance of generics, rapidly increasing geriatric population, increase in abbreviated new drug applications (ANDA) and increasing uptake of biopharmaceuticals. Government initiatives to encourage adoption of generics also provide an impetus for the growth of this market. For instance, in 2008, the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India, launched the Jan Aushadhi Scheme (Public Medicine Scheme) for providing quality medicines to the masses at affordable prices. Under this initiative, the government set up Jan Aushadhi stores to provide generic drugs to patients. Similarly, The European Union’s decentralized procedure (DCP) for drug approval is an effective system for cross-border collaboration on the authorization of medicines. This is being used as a model for a number of new global initiatives in the harmonization of pharmaceutical regulatory standards. The implementation of such standards in turn is expected to drive the adoption of generic drugs.

Emerging biosimilars market, increasing scope for HPAPIs, emerging markets and emerging technologies have opened an array of opportunities for the active pharmaceutical ingredients market. However, factors such as a stringent regulatory requirements and unfavorable drug price control policies across various countries may restrain the growth of this market.

Based on type, the market is segmented into innovative and generic APIs. On the basis of type of manufacture, the APIs market is categorized into two segments, captive manufacturer and merchant manufacturer. On the basis of type of synthesis, the APIs market is segmented into synthetic APIs and biotech APIs. On the basis of type of drug, the APIs market is segmented into prescription and over-the-counter APIs. On the basis of therapeutic application, the APIs market is further segmented into oncology, cardiovascular diseases, diabetes, endocrinology, central nervous system and neurological diseases and other therapeutic applications.

Research Coverage:

Apart from the comprehensive geographical and product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise basic views on key players in the active pharmaceutical ingredients market and their product portfolios, developments, and strategies. The above-mentioned market research data, current market size, and forecast of the future trends will help key players and new entrants to make the necessary decisions regarding product offerings, geographical focus, changes in strategic approach, R&D investments for innovations in products and technologies, and levels of output in order to remain successful.

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help firms garner a greater market share. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:
  • Market Penetration: Comprehensive information on the product portfolios of top players in the active pharmaceutical ingredients market. The report analyzes the active pharmaceutical ingredients market by application, sales channel, and region
  • Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and new product launches in the active pharmaceutical ingredients market
  • Competitive Assessment: In-depth assessment of market strategies, geographical and business segments, and product portfolios of leading players in the active pharmaceutical ingredients market
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the market for various active pharmaceutical ingredients products across geographies
  • Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the active pharmaceutical ingredients market
1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
  1.3.1 MARKETS COVERED
  1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 MARKET STAKEHOLDERS

2 RESEARCH METHODOLOGY

2.1 MARKET SIZE ESTIMATION
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION
2.3 KEY DATA FROM SECONDARY SOURCES
2.4 KEY DATA FROM PRIMARY SOURCES
2.5 KEY INDUSTRY INSIGHTS
2.6 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET OVERVIEW
4.2 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET. BY TYPE OF MANUFACTURER
4.3 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET. BY THERAPEUTIC AREA
4.4 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET. BY PRODUCT
4.5 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET. BY TYPE OF DRUG
4.6 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: GEOGRAPHIC SNAPSHOT

5 MARKET OVERVIEW

5.1 INTRODUCTION
5.2 MARKET DYNAMICS
  5.2.1 DRIVERS
    5.2.1.1 Increasing incidence of chronic diseases
    5.2.1.2 Rising prevalence of cancer
    5.2.1.3 Technological advancements in API manufacturing
    5.2.1.4 Growing importance of generics
    5.2.1.5 Rapidly increasing geriatric population
    5.2.1.6 Increase in abbreviated new drug applications (ANDA)
    5.2.1.7 Increasing uptake of biopharmaceuticals
  5.2.2 RESTRAINTS
    5.2.2.1 Stringent regulatory requirements
    5.2.2.2 Unfavorable drug price control policies across various countries
  5.2.3 OPPORTUNITIES
    5.2.3.1 Emerging biosimilars market
    5.2.3.2 Increasing scope for high-potency active pharmaceutical ingredients
    5.2.3.3 Emerging markets
    5.2.3.4 Emerging technologies
  5.2.4 CHALLENGES
    5.2.4.1 Product differentiation
    5.2.4.2 High manufacturing costs

6 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET. BY TYPE

6.1 INTRODUCTION
6.2 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS
6.3 GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS

7 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET. BY TYPE OF MANUFACTURER

7.1 INTRODUCTION
7.2 CAPTIVE MANUFACTURERS
7.3 MERCHANT API MANUFACTURERS
  7.3.1 MERCHANT MANUFACTURERS MARKET. BY TYPE
    7.3.1.1 Innovative merchant API manufacturers
    7.3.1.2 Generic merchant API manufacturers
  7.3.2 MERCHANT API MANUFACTURERS MARKET. BY MODE OF SYNTHESIS
    7.3.2.1 Synthetic APIs
    7.3.2.2 Biotech APIs

8 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET. BY TYPE OF SYNTHESIS

8.1 INTRODUCTION
8.2 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS
  8.2.1 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET. BY TYPE
    8.2.1.1 Innovative synthetic APIs
    8.2.1.2 Generic synthetic APIs
8.3 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS
  8.3.1 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET. BY TYPE
    8.3.1.1 Innovative biotech APIs
    8.3.1.2 Biosimilars
  8.3.2 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET. BY PRODUCT
    8.3.2.1 Monoclonal antibodies
    8.3.2.2 Vaccines
    8.3.2.3 Hormones and growth factors
    8.3.2.4 Cytokines
    8.3.2.5 Fusion proteins
    8.3.2.6 Therapeutic enzymes
    8.3.2.7 Blood factors
  8.3.3 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET. BY EXPRESSION SYSTEM
    8.3.3.1 Mammalian expression systems
    8.3.3.2 Microbial expression systems
    8.3.3.3 Yeast expression systems
    8.3.3.4 Plant expression systems
    8.3.3.5 Insect expression systems

9 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET. BY TYPE OF DRUG

9.1 INTRODUCTION
9.2 PRESCRIPTION DRUGS
9.3 OVER-THE-COUNTER DRUGS
9.4 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET. BY POTENCY
  9.4.1 LOW TO MODERATE POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS
  9.4.2 POTENT TO HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENTS

10 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET. BY THERAPEUTIC APPLICATION

10.1 INTRODUCTION
10.2 ONCOLOGY
10.3 CARDIOVASCULAR DISEASE
10.4 DIABETES
10.5 CENTRAL NERVOUS SYSTEM AND NEUROLOGICAL DISORDERS
10.6 ENDOCRINOLOGY
10.7 OTHER THERAPEUTIC APPLICATIONS

11 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET. BY REGION

11.1 INTRODUCTION
11.2 NORTH AMERICA
  11.2.1 U.S.
  11.2.2 CANADA
11.3 EUROPE
  11.3.1 GERMANY
  11.3.2 FRANCE
  11.3.3 U.K.
  11.3.4 ITALY
  11.3.5 SPAIN
  11.3.6 REST OF EUROPE (ROE)
11.4 ASIA
  11.4.1 JAPAN
  11.4.2 CHINA
  11.4.3 INDIA
  11.4.4 SOUTH KOREA
  11.4.5 REST OF ASIA (ROA)
11.5 REST OF THE WORLD (ROW)

12 COMPETITIVE LANDSCAPE

12.1 OVERVIEW
12.2 MARKET PLAYER RANKING
12.3 COMPETITIVE SITUATION AND TRENDS
  12.3.1 AGREEMENTS. COLLABORATIONS. PARTNERSHIPS. JOINT VENTURES. AND ALLIANCES
  12.3.2 REGULATORY APPROVALS
  12.3.3 MERGERS AND ACQUISITIONS
  12.3.4 EXPANSIONS
  12.3.5 INVESTMENTS

13 COMPANY PROFILES

(Overview. Financials. Products & Services. Strategy. and Developments)*

13.1 INTRODUCTION
13.2 PFIZER. INC.
13.3 NOVARTIS INTERNATIONAL AG
13.4 SANOFI
13.5 BOEHRINGER INGELHEIM
13.6 BRISTOL-MYERS SQUIBB
13.7 TEVA PHARMACEUTICAL INDUSTRIES LTD.
13.8 ELI LILLY AND COMPANY
13.9 GLAXOSMITHKLINE PLC
13.1 MERCK & CO.. INC.
13.11 ABBVIE INC.

*Details on overview. financials. product & services. strategy. and developments might not be captured in case of unlisted companies.

14 APPENDIX

14.1 INSIGHTS FROM INDUSTRY EXPERTS
14.2 DISCUSSION GUIDE
14.3 OTHER DEVELOPMENTS
14.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
14.5 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.6 AVAILABLE CUSTOMIZATIONS
14.7 RELATED REPORTS
14.8 AUTHOR DETAILS

LIST OF TABLES

Table 1 INDICATIVE LIST OF GENERIC DRUGS THAT GAINED APPROVAL IN 2016
Table 2 STATISTICS ON AGING POPULATION
Table 3 INDICATIVE LIST OF BIOLOGICS THAT GAINED U.S. REGULATORY APPROVAL IN 2015–2016
Table 4 INCREASING INCIDENCE OF CHRONIC DISEASES: A MAJOR MARKET DRIVER
Table 5 STRINGENT REGULATORY REQUIREMENTS: A MAJOR RESTRAINT FOR MARKET GROWTH
Table 6 EMERGING MARKETS OFFER SIGNIFICANT GROWTH OPPORTUNITIES
Table 7 STRINGENT REGULATORY GUIDELINES: A MAJOR CHALLENGE FOR MARKET GROWTH
Table 8 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE,2014-2021 (USD BILLION)
Table 9 INDICATIVE LIST OF NEW MOLECULAR ENTITIES THAT GAINED U.S. FDA APPROVAL IN 2016
Table 10 SIGNIFICANT PATENT EXPIRIES, 2015
Table 11 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2014-2021 (USD BILLION)
Table 12 NORTH AMERICA: INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2014-2021 (USD BILLION)
Table 13 EUROPE: INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2014-2021 (USD BILLION)
Table 14 ASIA: INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2014-2021 (USD BILLION)
Table 15 GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2014-2021 (USD BILLION)
Table 16 NORTH AMERICA: GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2014-2021 (USD BILLION)
Table 17 EUROPE: GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2014-2021 (USD BILLION)
Table 18 ASIA: GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2014-2021 (USD BILLION)
Table 19 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF MANUFACTURER, 2014–2021 (USD BILLION)
Table 20 CAPTIVE API MANUFACTURERS MARKET SIZE, BY REGION,2014–2021 (USD BILLION)
Table 21 NORTH AMERICA: CAPTIVE API MANUFACTURERS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 22 EUROPE: CAPTIVE API MANUFACTURERS MARKET SIZE, BY COUNTRY,2014–2021 (USD BILLION)
Table 23 ASIA: CAPTIVE API MANUFACTURERS MARKET SIZE, BY COUNTRY,2014–2021 (USD BILLION)
Table 24 LIST OF SIGNIFICANT MERGERS AND ACQUISITIONS IN THE CMO/CDMO INDUSTRY
Table 25 LIST OF SIGNIFICANT CMO/CDMO FACILITY EXPANSIONS
Table 26 MERCHANT API MANUFACTURERS MARKET SIZE, BY REGION,2014–2021 (USD BILLION)
Table 27 NORTH AMERICA: MERCHANT API MANUFACTURERS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 28 EUROPE: MERCHANT API MANUFACTURERS MARKET SIZE, BY COUNTRY,2014–2021 (USD BILLION)
Table 29 ASIA: MERCHANT API MANUFACTURERS MARKET SIZE, BY COUNTRY,2014–2021 (USD BILLION)
Table 30 MERCHANT API MANUFACTURERS MARKET SIZE, BY TYPE,2014–2021 (USD BILLION)
Table 31 INNOVATIVE MERCHANT API MANUFACTURERS MARKET SIZE, BY REGION,2014–2021 (USD BILLION)
Table 32 NORTH AMERICA: INNOVATIVE MERCHANT API MANUFACTURERS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 33 EUROPE: INNOVATIVE MERCHANT API MANUFACTURERS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 34 ASIA: INNOVATIVE MERCHANT API MANUFACTURERS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 35 GENERIC MERCHANT API MANUFACTURERS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION)
Table 36 NORTH AMERICA: GENERIC MERCHANT API MANUFACTURERS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 37 EUROPE: GENERIC MERCHANT API MANUFACTURERS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 38 ASIA: GENERIC MERCHANT API MANUFACTURERS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 39 MERCHANT API MANUFACTURERS MARKET SIZE, BY MODE OF SYNTHESIS, 2014–2021 (USD BILLION)
Table 40 MERCHANT SYNTHETIC API MANUFACTURERS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION)
Table 41 NORTH AMERICA: MERCHANT SYNTHETIC API MANUFACTURERS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 42 EUROPE: MERCHANT SYNTHETIC API MANUFACTURERS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 43 ASIA: MERCHANT SYNTHETIC API MANUFACTURERS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 44 MERCHANT BIOTECH API MANUFACTURERS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION)
Table 45 NORTH AMERICA: MERCHANT BIOTECH API MANUFACTURERS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 46 EUROPE: MERCHANT BIOTECH API MANUFACTURERS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 47 ASIA: MERCHANT BIOTECH API MANUFACTURERS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 48 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2014–2021 (USD BILLION)
Table 49 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION)
Table 50 NORTH AMERICA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 51 EUROPE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 52 ASIA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 53 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 54 INNOVATIVE SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION)
Table 55 NORTH AMERICA: INNOVATIVE SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 56 EUROPE: INNOVATIVE SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 57 ASIA: INNOVATIVE SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 58 GENERIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION)
Table 59 NORTH AMERICA: GENERIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 60 EUROPE: GENERIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 61 ASIA: GENERIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 62 TOP SELLING BIOLOGICS (2015)
Table 63 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION)
Table 64 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 65 EUROPE: BIOTECH PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 66 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 67 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 68 INNOVATIVE BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION)
Table 69 NORTH AMERICA: INNOVATIVE BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 70 EUROPE: INNOVATIVE BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 71 ASIA: INNOVATIVE BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 72 BIOSIMILARS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION)
Table 73 NORTH AMERICA: BIOSIMILARS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 74 EUROPE: BIOSIMILARS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 75 ASIA: BIOSIMILARS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 76 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2014–2021 (USD BILLION)
Table 77 INDICATIVE LIST OF MONOCLONAL ANTIBODIES THAT RECEIVED FDA APPROVAL IN 2016
Table 78 MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2014–2021 (USD BILLION)
Table 79 NORTH AMERICA: MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 80 EUROPE: MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 81 ASIA: MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 82 VACCINES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 83 NORTH AMERICA: VACCINES MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 84 EUROPE: VACCINES MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 85 ASIA: VACCINES MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 86 HORMONES AND GROWTH FACTORS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION)
Table 87 NORTH AMERICA: HORMONES AND GROWTH FACTORS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 88 EUROPE: HORMONES AND GROWTH FACTORS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 89 ASIA: HORMONES AND GROWTH FACTORS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 90 CYTOKINES MARKET SIZE, BY REGION, 2014–2021 (USD BILLION)
Table 91 NORTH AMERICA: CYTOKINES MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 92 EUROPE: CYTOKINES MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 93 ASIA: CYTOKINES MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 94 FUSION PROTEINS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION)
Table 95 NORTH AMERICA: FUSION PROTEINS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 96 EUROPE: FUSION PROTEINS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 97 ASIA: FUSION PROTEINS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 98 THERAPEUTIC ENZYMES MARKET SIZE, BY REGION, 2014–2021 (USD BILLION)
Table 99 NORTH AMERICA: THERAPEUTIC ENZYMES MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 100 EUROPE: THERAPEUTIC ENZYMES MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 101 ASIA: MERCHANT THERAPEUTIC ENZYMES MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 102 BLOOD FACTORS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 103 NORTH AMERICA: BLOOD FACTORS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 104 EUROPE: BLOOD FACTORS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 105 ASIA: BLOOD FACTORS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 106 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY EXPRESSION SYSTEM, 2014–2021 (USD BILLION)
Table 107 MAMMALIAN EXPRESSION SYSTEMS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION)
Table 108 NORTH AMERICA: MAMMALIAN EXPRESSION SYSTEMS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 109 EUROPE: MAMMALIAN EXPRESSION SYSTEMS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 110 ASIA: MAMMALIAN EXPRESSION SYSTEMS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 111 MICROBIAL EXPRESSION SYSTEMS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION)
Table 112 NORTH AMERICA: MICROBIAL EXPRESSION SYSTEMS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 113 EUROPE: MICROBIAL EXPRESSION SYSTEMS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 114 ASIA: MICROBIAL EXPRESSION SYSTEMS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 115 YEAST EXPRESSION SYSTEMS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION)
Table 116 NORTH AMERICA: YEAST EXPRESSION SYSTEMS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 117 EUROPE: YEAST EXPRESSION SYSTEMS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 118 ASIA: YEAST EXPRESSION SYSTEMS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 119 PLANT EXPRESSION SYSTEMS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION)
Table 120 NORTH AMERICA: PLANT EXPRESSION SYSTEMS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 121 EUROPE: PLANT EXPRESSION SYSTEMS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 122 ASIA: OTHER EXPRESSION SYSTEMS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 123 INSECT EXPRESSION SYSTEMS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION)
Table 124 NORTH AMERICA: INSECT EXPRESSION SYSTEMS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 125 EUROPE: INSECT EXPRESSION SYSTEMS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 126 ASIA: INSECT EXPRESSION SYSTEMS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 127 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF DRUG, 2014–2021 (USD BILLION)
Table 128 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR PRESCRIPTION DRUGS, BY REGION, 2014–2021 (USD BILLION)
Table 129 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR PRESCRIPTION DRUGS, BY COUNTRY, 2014–2021 (USD BILLION)
Table 130 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR PRESCRIPTION DRUGS, BY COUNTRY, 2014–2021 (USD BILLION)
Table 131 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR PRESCRIPTION DRUGS, COUNTRY, 2014–2021 (USD BILLION)
Table 132 PRESCRIPTION-TO-OTC SWITCH LIST IN THE U.S.
Table 133 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR OVER-THE-COUNTER DRUGS, BY REGION, 2014–2021 (USD BILLION)
Table 134 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2014–2021 (USD BILLION)
Table 135 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2014–2021 (USD BILLION)
Table 136 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2014–2021 (USD BILLION)
Table 137 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY POTENCY, 2014-2021 (USD BILLION)
Table 138 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2014–2021 (USD BILLION)
Table 139 CANCER: ESTIMATED INCIDENCE, MORTALITY, AND PREVALENCE (2012)
Table 140 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR ONCOLOGY, BY REGION, 2014–2021 (USD BILLION)
Table 141 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR ONCOLOGY, BY COUNTRY, 2014–2021 (USD BILLION)
Table 142 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR ONCOLOGY, BY COUNTRY, 2014–2021 (USD BILLION)
Table 143 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR ONCOLOGY, BY COUNTRY, 2014–2021 (USD BILLION)
Table 144 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR CVD, BY REGION, 2014–2021 (USD BILLION)
Table 145 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR CVD, BY COUNTRY, 2014–2021 (USD BILLION)
Table 146 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR CVD, BY COUNTRY, 2014–2021 (USD BILLION)
Table 147 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR CVD, BY COUNTRY, 2014–2021 (USD BILLION)
Table 148 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR DIABETES, BY REGION, 2014–2021 (USD BILLION)
Table 149 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR DIABETES, BY COUNTRY, 2014–2021 (USD BILLION)
Table 150 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR DIABETES, BY COUNTRY, 2014–2021 (USD BILLION)
Table 151 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR DIABETES, BY COUNTRY, 2014–2021 (USD BILLION)
Table 152 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR CNS AND NEUROLOGICAL DISORDERS, BY REGION, 2014–2021 (USD BILLION)
Table 153 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR CNS AND NEUROLOGICAL DISORDERS, BY COUNTRY, 2014–2021 (USD BILLION)
Table 154 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR CNS AND NEUROLOGICAL DISORDERS, BY COUNTRY, 2014–2021 (USD BILLION)
Table 155 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR CNS AND NEUROLOGICAL DISORDERS, BY COUNTRY, 2014–2021 (USD BILLION)
Table 156 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR ENDOCRINOLOGY, BY REGION, 2014–2021 (USD BILLION)
Table 157 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR ENDOCRINOLOGY, BY COUNTRY, 2014–2021 (USD BILLION)
Table 158 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR ENDOCRINOLOGY, BY COUNTRY, 2014–2021 (USD BILLION)
Table 159 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR ENDOCRINOLOGY, BY COUNTRY, 2014–2021 (USD BILLION)
Table 160 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2014–2021 (USD BILLION)
Table 161 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2014–2021 (USD BILLION)
Table 162 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2014–2021 (USD BILLION)
Table 163 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2014–2021 (USD BILLION)
Table 164 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION)
Table 165 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 166 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 167 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF MANUFACTURER, 2014–2021 (USD BILLION)
Table 168 NORTH AMERICA: MERCHANT API MANUFACTURERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 169 NORTH AMERICA: MERCHANT API MANUFACTURERS MARKET SIZE, BY MODE OF SYNTHESIS, 2014–2021 (USD BILLION)
Table 170 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MODE OF SYNTHESIS, 2014–2021 (USD BILLION)
Table 171 NORTH AMERICA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 172 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 173 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2014–2021 (USD BILLION)
Table 174 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF EXPRESSION SYSTEM, 2014–2021 (USD BILLION)
Table 175 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF DRUG, 2014–2021 (USD BILLION)
Table 176 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2014–2021 (USD BILLION)
Table 177 RECENT FDA APPROVALS FOR NDA AND ANDA
Table 178 U.S.: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 179 U.S.: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF MANUFACTURER, 2014–2021 (USD BILLION)
Table 180 U.S.: MERCHANT API MANUFACTURERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 181 U.S.: MERCHANT API MANUFACTURERS MARKET SIZE, BY MODE OF SYNTHESIS, 2014–2021 (USD BILLION)
Table 182 U.S.: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MODE OF SYNTHESIS, 2014–2021 (USD BILLION)
Table 183 U.S.: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 184 U.S.: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 185 U.S.: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2014–2021 (USD BILLION)
Table 186 U.S.: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF EXPRESSION SYSTEM, 2014–2021 (USD BILLION)
Table 187 U.S.: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF DRUG, 2014–2021 (USD BILLION)
Table 188 U.S.: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2014–2021 (USD BILLION)
Table 189 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 190 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF MANUFACTURER, 2014–2021 (USD BILLION)
Table 191 CANADA: MERCHANT API MANUFACTURERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 192 CANADA: MERCHANT API MANUFACTURERS MARKET SIZE, BY MODE OF SYNTHESIS, 2014–2021 (USD BILLION)
Table 193 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MODE OF SYNTHESIS, 2014–2021 (USD BILLION)
Table 194 CANADA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 195 CANADA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 196 CANADA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)
Table 197 CANADA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF EXPRESSION SYSTEM, 2014–2021 (USD BILLION)
Table 198 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF DRUG, 2014–2021 (USD BILLION)
Table 199 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2014–2021 (USD BILLION)
Table 200 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 201 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF MANUFACTURER, 2014–2021 (USD BILLION)
Table 202 EUROPE: MERCHANT API MANUFACTURERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 203 EUROPE: MERCHANT API MANUFACTURERS MARKET SIZE, BY MODE OF SYNTHESIS, 2014–2021 (USD BILLION)
Table 204 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MODE OF SYNTHESIS, 2014–2021 (USD BILLION)
Table 205 EUROPE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 206 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 207 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2014–2021 (USD BILLION)
Table 208 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF EXPRESSION SYSTEM, 2014–2021 (USD BILLION)
Table 209 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF DRUG, 2014–2021 (USD BILLION)
Table 210 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2014–2021 (USD BILLION)
Table 211 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 212 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF MANUFACTURER, 2014–2021 (USD BILLION)
Table 213 GERMANY: MERCHANT API MANUFACTURERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 214 GERMANY: MERCHANT API MANUFACTURERS MARKET SIZE, BY MODE OF SYNTHESIS, 2014–2021 (USD BILLION)
Table 215 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MODE OF SYNTHESIS, 2014–2021 (USD BILLION)
Table 216 GERMANY: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 217 GERMANY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 218 GERMANY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)
Table 219 GERMANY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF EXPRESSION SYSTEM, 2014–2021 (USD BILLION)
Table 220 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF DRUG, 2014–2021 (USD BILLION)
Table 221 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2014–2021 (USD BILLION)
Table 222 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 223 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF MANUFACTURER, 2014–2021 (USD BILLION)
Table 224 FRANCE: MERCHANT API MANUFACTURERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 225 FRANCE: MERCHANT API MANUFACTURERS MARKET SIZE, BY MODE OF SYNTHESIS, 2014–2021 (USD BILLION)
Table 226 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MODE OF SYNTHESIS, 2014–2021 (USD BILLION)
Table 227 FRANCE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 228 FRANCE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 229 FRANCE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)
Table 230 FRANCE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF EXPRESSION SYSTEM, 2014–2021 (USD BILLION)
Table 231 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF DRUG, 2014–2021 (USD BILLION)
Table 232 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2014–2021 (USD BILLION)
Table 233 U.K.: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 234 U.K.: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF MANUFACTURER, 2014–2021 (USD BILLION)
Table 235 U.K.: MERCHANT API MANUFACTURERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 236 U.K.: MERCHANT API MANUFACTURERS MARKET SIZE, BY MODE OF SYNTHESIS, 2014–2021 (USD BILLION)
Table 237 U.K.: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MODE OF SYNTHESIS, 2014–2021 (USD BILLION)
Table 238 U.K.: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 239 U.K.: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 240 U.K.: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)
Table 241 U.K.: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF EXPRESSION SYSTEM, 2014–2021 (USD MILLION)
Table 242 U.K.: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF DRUG, 2014–2021 (USD BILLION)
Table 243 U.K.: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2014–2021 (USD BILLION)
Table 244 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 245 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF MANUFACTURER, 2014–2021 (USD BILLION)
Table 246 ITALY: MERCHANT API MANUFACTURERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 247 ITALY: MERCHANT API MANUFACTURERS MARKET SIZE, BY MODE OF SYNTHESIS, 2014–2021 (USD BILLION)
Table 248 ITALIAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MODE OF SYNTHESIS, 2014–2021 (USD BILLION)
Table 249 ITALY: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 250 ITALY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 251 ITALY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)
Table 252 ITALY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF EXPRESSION SYSTEM, 2014–2021 (USD MILLION)
Table 253 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF DRUG, 2014–2021 (USD BILLION)
Table 254 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2014–2021 (USD BILLION)
Table 255 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 256 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF MANUFACTURER, 2014–2021 (USD BILLION)
Table 257 SPAIN: MERCHANT API MANUFACTURERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 258 SPAIN: MERCHANT API MANUFACTURERS MARKET SIZE, BY MODE OF SYNTHESIS, 2014–2021 (USD BILLION)
Table 259 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MODE OF SYNTHESIS, 2014–2021 (USD BILLION)
Table 260 SPAIN: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 261 SPAIN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 262 SPAIN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)
Table 263 SPAIN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF EXPRESSION SYSTEM, 2014–2021 (USD MILLION)
Table 264 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF DRUG, 2014–2021 (USD BILLION)
Table 265 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2014–2021 (USD BILLION)
Table 266 ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 267 ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF MANUFACTURER, 2014–2021 (USD BILLION)
Table 268 ROE: MERCHANT API MANUFACTURERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 269 ROE: MERCHANT API MANUFACTURERS MARKET SIZE, BY MODE OF SYNTHESIS, 2014–2021 (USD BILLION)
Table 270 ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MODE OF SYNTHESIS, 2014–2021 (USD BILLION)
Table 271 ROE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 272 ROE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 273 ROE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)
Table 274 ROE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF EXPRESSION SYSTEM, 2014–2021 (USD MILLION)
Table 275 ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF DRUG, 2014–2021 (USD BILLION)
Table 276 ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2014–2021 (USD BILLION)
Table 277 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 278 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF MANUFACTURER, 2014–2021 (USD BILLION)
Table 279 ASIA: MERCHANT API MANUFACTURERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 280 ASIA: MERCHANT API MANUFACTURERS MARKET SIZE, BY MODE OF SYNTHESIS, 2014–2021 (USD BILLION)
Table 281 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MODE OF SYNTHESIS, 2014–2021 (USD BILLION)
Table 282 ASIA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 283 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 284 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)
Table 285 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF EXPRESSION SYSTEM, 2014–2021 (USD BILLION)
Table 286 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF DRUG, 2014–2021 (USD BILLION)
Table 287 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2014–2021 (USD BILLION)
Table 288 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 289 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF MANUFACTURER, 2014–2021 (USD BILLION)
Table 290 JAPAN: MERCHANT API MANUFACTURERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 291 JAPAN: MERCHANT API MANUFACTURERS MARKET SIZE, BY MODE OF SYNTHESIS, 2014–2021 (USD BILLION)
Table 292 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MODE OF SYNTHESIS, 2014–2021 (USD BILLION)
Table 293 JAPAN: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 294 JAPAN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 295 JAPAN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)
Table 296 JAPAN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF EXPRESSION SYSTEM, 2014–2021 (USD MILLION)
Table 297 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF DRUG, 2014–2021 (USD BILLION)
Table 298 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2014–2021 (USD BILLION)
Table 299 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 300 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF MANUFACTURER, 2014–2021 (USD BILLION)
Table 301 CHINA: MERCHANT API MANUFACTURERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 302 CHINA: MERCHANT API MANUFACTURERS MARKET SIZE, BY MODE OF SYNTHESIS, 2014–2021 (USD BILLION)
Table 303 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MODE OF SYNTHESIS, 2014–2021 (USD BILLION)
Table 304 CHINA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 305 CHINA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 306 CHINA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)
Table 307 CHINA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF EXPRESSION SYSTEM, 2014–2021 (USD MILLION)
Table 308 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF DRUG, 2014–2021 (USD BILLION)
Table 309 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2014–2021 (USD BILLION)
Table 310 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 311 INDIAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF MANUFACTURER, 2014–2021 (USD BILLION)
Table 312 INDIA: MERCHANT API MANUFACTURERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 313 INDIA: MERCHANT API MANUFACTURERS MARKET SIZE, BY MODE OF SYNTHESIS, 2014–2021 (USD BILLION)
Table 314 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MODE OF SYNTHESIS, 2014–2021 (USD BILLION)
Table 315 INDIA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 316 INDIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 317 INDIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)
Table 318 INDIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF EXPRESSION SYSTEM, 2014–2021 (USD MILLION)
Table 319 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF DRUG, 2014–2021 (USD BILLION)
Table 320 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2014–2021 (USD BILLION)
Table 321 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 322 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF MANUFACTURER, 2014–2021 (USD BILLION)
Table 323 SOUTH KOREA: MERCHANT API MANUFACTURERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 324 SOUTH KOREA: MERCHANT API MANUFACTURERS MARKET SIZE, BY MODE OF SYNTHESIS, 2014–2021 (USD BILLION)
Table 325 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MODE OF SYNTHESIS, 2014–2021 (USD BILLION)
Table 326 SOUTH KOREA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 327 SOUTH KOREA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 328 SOUTH KOREA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)
Table 329 SOUTH KOREA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF EXPRESSION SYSTEM, 2014–2021 (USD MILLION)
Table 330 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF DRUG, 2014–2021 (USD BILLION)
Table 331 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2014–2021 (USD BILLION)
Table 332 ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 333 ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF MANUFACTURER, 2014–2021 (USD BILLION)
Table 334 ROA: MERCHANT API MANUFACTURERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 335 ROA: MERCHANT API MANUFACTURERS MARKET SIZE, BY MODE OF SYNTHESIS, 2014–2021 (USD BILLION)
Table 336 ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MODE OF SYNTHESIS, 2014–2021 (USD BILLION)
Table 337 ROA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 338 ROA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 339 ROA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)
Table 340 ROA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF EXPRESSION SYSTEM, 2014–2021 (USD MILLION)
Table 341 ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF DRUG, 2014–2021 (USD BILLION)
Table 342 ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2014–2021 (USD BILLION)
Table 343 ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 344 ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF MANUFACTURER, 2014–2021 (USD BILLION)
Table 345 ROW: MERCHANT API MANUFACTURERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 346 ROW: MERCHANT API MANUFACTURERS MARKET SIZE, BY MODE OF SYNTHESIS, 2014–2021 (USD BILLION)
Table 347 ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MODE OF SYNTHESIS, 2014–2021 (USD BILLION)
Table 348 ROW: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 349 ROW: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 350 ROW: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)
Table 351 ROW: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF EXPRESSION SYSTEM, 2014–2021 (USD BILLION)
Table 352 ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF DRUG, 2014–2021 (USD BILLION)
Table 353 ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2014–2021 (USD BILLION)
Table 354 AGREEMENTS, COLLABORATIONS, PARTNERSHIPS, JOINT VENTURES, AND ALLIANCES (2013–2016)
Table 355 REGULATORY APPROVALS (2013-2016)
Table 356 MERGERS AND ACQUISITIONS (2013-2016)
Table 357 EXPANSIONS (2013–2016)
Table 358 INVESTMENTS (2013–2016)
Table 359 EXCHANGE RATE (UTILIZED FOR THE CONVERSION OF EUR TO USD)
Table 360 EXCHANGE RATE (UTILIZED FOR THE CONVERSION OF GBP TO USD)
Table 361 PFIZER INC. (U.S.)
Table 362 NOVARTIS INTERNATIONAL AG (SWITZERLAND)
Table 363 SANOFI (FRANCE)
Table 364 BOEHRINGER INGELHEIM (GERMANY)
Table 365 BRISTOL-MYERS SQUIBB (U.S.)
Table 366 TEVA PHARMACEUTICAL INDUSTRIES LTD. (ISRAEL)
Table 367 GLAXOSMITHKLINE PLC (U.K.)
Table 368 MERCK & CO., INC. (U.S.)
Table 369 ABBVIE (U.S.)

LIST OF FIGURES

Figure 1 RESEARCH DESIGN
Figure 2 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
Figure 3 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
Figure 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
Figure 5 DATA TRIANGULATION METHODOLOGY
Figure 6 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2016 VS. 2021
Figure 7 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF MANUFACTURER, 2016 VS. 2021
Figure 8 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2016 VS. 2021
Figure 9 BIOTECH ACTIVE PHARMACEUTICALS INGREDIENTS MARKET SIZE, BY PRODUCT: MONOCLONAL ANTIBODIES TO DOMINATE THE MARKET IN 2016
Figure 10 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2016 VS. 2021
Figure 11 GEOGRAPHIC SNAPSHOT OF THE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
Figure 12 GROWING IMPORTANCE OF GENERICS, THE MAJOR FACTOR DRIVING THE GROWTH OF THE MARKET
Figure 13 CAPTIVE MANUFACTURERS SEGMENT TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2016
Figure 14 ONCOLOGY SEGMENT TO WITNESS HIGHEST GROWTH DURING THE FORECAST PERIOD
Figure 15 MONOCLONAL ANTIBODIES SEGMENT TO WITNESS HIGHEST GROWTH DURING THE FORECAST PERIOD
Figure 16 OVER-THE-COUNTER DRUGS TO WITNESS HIGHEST GROWTH FROM 2016–2021
Figure 17 ASIA TO WITNESS HIGHEST GROWTH IN THE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET DURING THE FORECAST PERIOD
Figure 18 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
Figure 19 INNOVATIVE SEGMENT TO DOMINATE THE MARKET IN 2016
Figure 20 CAPTIVE MANUFACTURERS TO DOMINATE THE MARKET IN 2016
Figure 21 NORTH AMERICA TO DOMINATE THE MARKET FOR CAPTIVE MANUFACTURERS IN 2016
Figure 22 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS SEGMENT TO DOMINATE THE MARKET IN 2016
Figure 23 NORTH AMERICA TO DOMINATE SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET IN 2016
Figure 24 PRESCRIPTION DRUGS TO DOMINATE THE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, IN 2016
Figure 25 LOW TO MODERATE SEGMENT TO DOMINATE THE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, IN 2016
Figure 26 ONCOLOGY SEGMENT TO DOMINATE THE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION
Figure 27 NORTH AMERICA TO DOMINATE THE ONCOLOGY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION
Figure 28 ASIA TO WITNESS HIGHEST GROWTH DURING THE FORECAST PERIOD (2016–2021)
Figure 29 NORTH AMERICA TO HOLD THE LARGEST SHARE OF THE GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET (2016)
Figure 30 EUROPEAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SNAPSHOT (2016)
Figure 31 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SNAPSHOT (2016)
Figure 32 ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SNAPSHOT
Figure 33 KEY DEVELOPMENTS IN THE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, 2013–2016
Figure 34 MARKET EVOLUTION FRAMEWORK—AGREEMENTS, PARTNERSHIPS, COLLABORATIONS, JOINT VENTURES, AND ALLIANCES FUELED MARKET GROWTH
Figure 35 BATTLE FOR MARKET SHARE: AGREEMENTS,PARTNERSHIPS,COLLABORATIONS,JOINT VENTURES,AND ALLIANCES WAS THE KEY STRATEGY ADOPTED BY MARKET PLAYERS (2013–2016)
Figure 36 GEOGRAPHIC MIX OF THE TOP 5 PLAYERS
Figure 37 PFIZER, INC.: COMPANY SNAPSHOT
Figure 38 NOVARTIS INTERNATIONAL AG: COMPANY SNAPSHOT
Figure 39 SANOFI: COMPANY SNAPSHOT
Figure 40 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
Figure 41 BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
Figure 42 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
Figure 43 ELI LILLY AND COMPANY: COMPANY SNAPSHOT
Figure 44 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
Figure 45 MERCK & CO., INC.: COMPANY SNAPSHOT
Figure 46 ABBVIE INC.: COMPANY SNAPSHOT
Skip to top


Ask Your Question

Active Pharmaceutical Ingredients/API Market by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormone) Drug (OTC, Rx), Therapy (Diabetes, Oncology, CNS, CVD) - Global Forecast to 2021
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: